Florence Cymbalista, MD, of Hôpital Avicenne, Bobigny, France, discusses challenges associated with the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and methods to overcome these, including combination with venetoclax as evaluated in the CLL14 study (NCT02242942) as well as BTK inhibitor use combined with immuno-chemotherapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).